2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159121
    sEH inhibitor-17 2823295-37-8 98%
    sEH inhibitor-17 (compound 4f) is an oral active soluble epoxide hydrolase (sEH) inhibitor with the IC50 of 2.94 nM. sEH inhibitor-17 shows anti-inflammatory efficacy.
    sEH inhibitor-17
  • HY-159131
    PNSC928 98%
    PNSC928 is an inhibitor for the CtBP2-p300 interaction with an IC50 of 23.60 µM, and reverses the Lipopolysaccharides (HY-D1056)-induced expressions of proinflammatory cytokines in RAW264.7. PNSC928 ameliorates the acute respiratory distress syndrome (ARDS)in mice.
    PNSC928
  • HY-159144
    Anti-inflammatory agent 91 98%
    Anti-inflammatory agent 91 (Compound 4o) is an anti-inflammatory agent that can reduce inflammatory cytokines by inhibiting the STAT3 and NF-κB signaling pathways. Anti-inflammatory agent 91 can be used in research to improve skin inflammation associated with psoriasis.
    Anti-inflammatory agent 91
  • HY-159146
    PPARα agonist 4 98%
    PPARα agonist 4 (compound BH400) is a PPARα agonist (EC50= 1.2 μM). PPARα agonist 4 also inhibits STING (IC50: 8.1 μM). PPARα agonist 4 reduces the CoCl2-induced production of ROS and LPS-induced secretion of IL-6. The PPARα agonist 4 restores the decreased expression of PCG1α induced by LPS.
    PPARα agonist 4
  • HY-159157
    Anti-inflammatory agent 92 1609387-77-0 98%
    Anti-inflammatory agent 92 (compound LD4) is a porphyrin derivative. Anti-inflammatory agent 92 has anti-inflammatory properties. Anti-inflammatory agent 92 can alleviate ulcerative colitis by inhibiting the STAT3-EPHX2 axis.
    Anti-inflammatory agent 92
  • HY-159158
    COX-1/2-IN-8 98%
    COX-1/2-IN-8 (compound 11f) is an orally active and potent inhibitor of COX-1 and COX-2, with IC50 values of 2.14 and 0.58 µM, respectively. COX-1/2-IN-8 displays a higher significant anti-inflammatory activity than Celecoxib (HY-14398).
    COX-1/2-IN-8
  • HY-159159
    MS-II-124 3037332-85-4 98%
    MS-II-124 is an effective and selective NLRP3 inhibitor (IC50=0.12 μM) with anti-inflammatory and immunomodulatory activities, which can be used in the research of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS).
    MS-II-124
  • HY-159169
    5-LOX/sEH-IN-1 98%
    5-LOX/sEH-IN-1 (Compound 8o) is a dual 5-LOX/sEH-IN-1 inhibitor with cardioprotective effects, exhibiting IC50 values of 3.05 μM and 2.20 nM respectively, and 5-LOX/sEH-IN-1 can also inhibit the activity of COX-2 (IC50=10.50 μM). 5-LOX/sEH-IN-1 has analgesic and anti-inflammatory effects, while reducing ulcer pathogenicity, and can be used to develop anti-inflammatory agents with fewer gastrointestinal and cardiovascular side effects.
    5-LOX/sEH-IN-1
  • HY-159171
    sEH/HDAC6-IN-2 3009011-58-6 98%
    sEH/HDAC6-IN-2 is a potent dual soluble epoxide hydrolase (sEH) and HDAC6 inhibitor with IC50s of 0.9 nM, 46.8 nM, and 8 nM for human sEH, mouse sEH, and HDAC6, respectively. sEH/HDAC6-IN-2 can be used for the study of inflammatory pain.
    sEH/HDAC6-IN-2
  • HY-159178
    m-AM-BBIQ 1258457-58-7 98%
    m-AM-BBIQ (compound 10) is a dual TLR7 and TLR8 agonist, with EC50 values of 0.12 μM and 1.7 μM for hTLR7 and hTLR8, respectively.
    m-AM-BBIQ
  • HY-159179
    α4 integrin receptor antagonist 3 863226-74-8 98%
    α4 integrin receptor antagonist 3 (Compound 11) is an orally active α4integrin receptor antagonist. α4 integrin receptor antagonist 3 can inhibit the adhesion of K562 cells mediated by the interaction between α4β1/VCAM-1 and α4β7/MAdCAM-1, with IC50 values of 130 nM and 2 nM, respectively. α4 integrin receptor antagonist 3 has the potential to be used in the study of dextran sulfate sodium (DSS) colitis mouse model.
    α4 integrin receptor antagonist 3
  • HY-159481
    SDH-IN-17 98%
    SDH-IN-17 (compound C32), a hydrazide-containing flavonol derivative, is a potent succinate dehydrogenase (SDH) inhibitor with an IC50 of 8.42 μM. SDH-IN-17 can occupy the active site and form strong interactions with the key residues of SDH. SDH-IN-17 exhibits antifungal activity against Rhizoctonia solani (EC50=0.170 μg/mL). SDH-IN-17 disrupts the normal growth of hyphae by affecting the structural integrity of the cell membrane and cellular respiration. SDH-IN-17 has the potential for plant disease control research.
    SDH-IN-17
  • HY-159514
    Graveolide 72173-44-5 98%
    Graveolide (Compound 5) is a sesquiterpenoid compound that can be isolated from C. abrotanoides. Graveolide possesses anti-inflammatory activity and can be utilized in the research of atopic dermatitis.
    Graveolide
  • HY-159516
    Sabialimon P 2267333-96-8 98%
    Sabialimon P (compound 16) is a NO release inhibitor (IC50=18.12 μM) with anti-inflammatory activity. Sabialimon P significantly reduces the secretion of TNF-α, iNOS, IL-6 and NF-κB and inhibits the expression of COX-2 and NF-κB/p65 in RAW264.7 cells induced by LPS (HY-D1056).
    Sabialimon P
  • HY-159561
    COX-1-IN-2 98%
    COX-1-IN-2 (compound 5h) is an anti-inflammatory agent with potent analgesic activity. COX-1-IN-2 exhibits a significant inhibitory effect on COX-1 (IC50=38.76 nM).
    COX-1-IN-2
  • HY-159562
    COX-2-IN-46 98%
    COX-2-IN-46 (compound 5m) is an anti-inflammatory agent with potent analgesic activity. COX-2-IN-46 exhibits a significant inhibitory effect on COX-2 (IC50=87.74 nM).
    COX-2-IN-46
  • HY-159564
    iNOS/COX-2-IN-3 98%
    iNOS/COX-2-IN-3 (compound 7d) is a dual inhibitor of iNOS and COX-2, with potential anti-inflammatory activity against LPS (HY-D1056)-induced RAW 264.7 cells (IC50=3.48 μM). iNOS/COX-2-IN-3 has good plasma stability, oral activity and gastric safety, and its inhibitory activity on iNOS and COX-2 expression is 5.43-fold and 2.37-fold that of Indomethacin (HY-14397), respectively.
    iNOS/COX-2-IN-3
  • HY-159655
    PLpro-IN-6 3041046-04-9 98%
    PLpro-IN-6 (compound 6) is a papain-like protease (PLpro) inhibitor, with an IC50 of 0.019 μM for SARS CoV2 PLpro enzyme.
    PLpro-IN-6
  • HY-159669
    Stercobilin hydrochloride (mixture of isomers) 13129-80-1 98%
    Stercobilin hydrochloride (amixture of isomers) is a bile pigment metabolized by gut bacteria, and it's also an HIV protease inhibitor, with a Ki of 4 μM. Stercobilin hydrochloride (a mixture of isomers) can induce pro-inflammatory activity in mouse macrophage RAW264 cells, including the production of TNF-α and IL-1β. Stercobilin hydrochloride (a mixture of isomers) can be used in studies of inflammation and viral infections.
    Stercobilin hydrochloride (mixture of isomers)
  • HY-159675
    1-A-N 98%
    1-A-N is a lipid nanoparticle (LNP) used for in vivo delivery of siRNA. 1-A-N can regulate immune response by delivering siCD45 (siRNA targeting CD45) to T cells and silencing the CD45 gene.
    1-A-N
Cat. No. Product Name / Synonyms Application Reactivity